New drug cocktail aims to tame stubborn lymphoma
NCT ID NCT07195799
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests a combination of the experimental drug linperlisib plus three standard chemotherapy drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to see how well the combo shrinks tumors and controls the disease. Participants will receive the treatment and be monitored for response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.